Scientific Presentations

November 2021

TNX-601 CR*: a Once-Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder

November 2021

TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial

July 2020

Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)

June 2021

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

June 2021

Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD

June 2020

Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer

January 2020

Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*

November 2019

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

May 2019

Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP

November 2018

Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD

November 2018

Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)

August 2017

Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response

August 2017

Efficacy and Safety of a Low Dose, Bedtime, Proprietary, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL#) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301)

August 2018

Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies

May 2018

Including Suicidal Individuals in Treatment Trials: Treatment of Military-Related PTSD with TNX-102 SL, a Novel Sublingual Formulation of Cyclobenzaprine Hypothesized to Address PTSD through Improvement in Sleep Quality

June 2017

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

May 2017

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

May 2017

Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response

December 2016

The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX – 102 SL in the Treatment of Military-Related PTSD

November 2016

Low-Dose Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD: Results of a Phase 2 Randomized, Placebo-Controlled Multicenter Trial

November 2016

The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD

October 2016

A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD: Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Gregory Sullivan – Results of the Phase 2 “AtEase Study” in Military-Related PTSD

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Jonathan Davidson – A Review of Pharmacotherapy for PTSD

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Thomas A. Mellman – Focus on Sleep and PTSD Treatment Populations

August 2016

The AtEase Study: Efficacy and Safety of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

June 2016

TNX-102 SL for the Treatment of Fibromyalgia — Comparison of 30% Pain Respondent Analysis with Omeract Draft Composite Responder Endpoint Analyses

June 2016

A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

May 2016

A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

March 2016

Rapid Sublingual Absorption of Cyclobenzaprine (CBP) with Basifying Agents: Prospect for Bedtime Treatment of Fibromyalgia Syndrome (FM) Presentation Number: LB-026

November 2015

Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)

November 2015

Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)

November 2015

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study

November 2015

An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD

November 2015

Comparative Neuropharmacology of Therapeutic Agents Targeting Posttraumatic Stress Disorder

June 2015

Serotonin Receptor Profiles of Bedtime Pharmacotherapies Targeting Posttraumatic Stress Disorder (PTSD)

June 2015

TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement

June 2015

TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization

August 2015

The (R)-isomer of isometheptene, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models

August 2015

The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

August 2015

(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache

November 2013

Cyclobenzaprine (CBP) and its Major Metabolite Norcyclobenzaprine (nCBP) are Potent Antagonists of the Serotonin Receptor 2A, Histamine H1 and α-Adrenergic Receptors: Mechanistic and Safety Implications…